NCT05449405View on ClinicalTrials.gov

Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

December 7, 2021

Primary Completion Date

March 11, 2022

Study Completion Date

March 11, 2022

Conditions
COVID-19Symptoms and SignsCOVID-19 PandemicCoronavirus Disease 2019Coronavirus Infections
Interventions
COMBINATION_PRODUCT

Chlorpheniramine Maleate 1% Nasal Spray

Chlorpheniramine Maleate 1% Nasal Spray

COMBINATION_PRODUCT

Placebo

Placebo nasal spray

Trial Locations (1)

Unknown

Hospital CEMESA, Cortés

Sponsors
All Listed Sponsors
collaborator

Hospital CEMESA Cortés, San Pedro Sula, Honduras

UNKNOWN

lead

Dr. Ferrer BioPharma

INDUSTRY

NCT05449405 - Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I | Biotech Hunter | Biotech Hunter